Sector News

Medtronic launches Infinity upper spine surgery immobilization system

October 8, 2018
Life sciences

Medtronic launched a surgical system in the U.S. designed to immobilize the thoracic and cervical spine during complex procedures and assist surgeons with navigation.

The Infinity Occipitocervical-Upper Thoracic System features a multi-axial screw that can move 60 degrees in any direction, as well as 3.0mm and 5.5mm diameter screws for a range of patient demographics and clinical applications.

The system also includes a spectrum of implant materials and sizes, and can be paired with the company’s O-arm imaging and StealthStation navigation systems.

Medtronic announced the launch during the annual meeting of the North American Spine Society in Los Angeles, and plans to make the system available globally over the next year. The Infinity OCT System is indicated for conditions including degenerative disc disease, instability or deformity, tumors, and traumatic spinal fractures or traumatic dislocations.

Last month, Medtronic announced it would acquire the remainder of Mazor Robotics, a developer of digitally-assisted spine surgery guidance systems, and plans to merge the company with its own implants, navigation and imaging products.

The $1.6 billion deal is the culmination of a phased investment agreement between the two companies that began in 2016, and Medtronic plans to maintain Mazor’s site and team in Caesarea, Israel.

“We believe robotic-assisted procedures are the future of spine surgery, enhancing surgeons’ abilities to perform complex procedures with greater precision, consistency and control,” Geoff Martha, president of Medtronic’s Restorative Therapies Group, said at the time.

By: Conor Hale

Source: Fierce Biotech

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.